Congress clarifies opioid grants can fund public naloxone kits

What it does

This bill amends the 21st Century Cures Act to allow states and tribes to use existing federal opioid-response grants to purchase, distribute, and maintain public access overdose reversal kits (naloxone/Narcan). It adds a definition of what counts as a 'public access opioid overdose reversal kit' to clarify eligible uses of grant funds already appropriated for opioid disorder response.

Why we flagged it

The bill is a narrow, technical amendment to existing opioid-response law that clarifies eligible uses of federal grants. It is not a new appropriation, new agency, or new program—it is a definitional clarification enabling states and tribes to deploy overdose-reversal kits using money already designated for opioid response.

What the text implies

• The bill does not appropriate new money; it clarifies use of existing grants. Implementation depends on whether states and tribes choose to reallocate existing opioid-response budgets toward kits rather than other interventions (treatment, prevention, recovery services). No guarantee of increased kit distribution if states prioritize other uses.
• Public access kits require ongoing maintenance and replacement; the bill permits grant funds to cover this, but does not specify funding levels or timelines, leaving sustainability dependent on state/tribal budget decisions.
• The definition of 'public access opioid overdose reversal kit' is narrow (medication + instructions) and does not address training, liability, or Good Samaritan protections, which vary by state and may limit actual public deployment.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands the permitted use of already-appropriated federal opioid-response grants to include public access naloxone kits, which directly reduce overdose deaths. Citizens in communities with public access kits have better survival odds in overdose emergencies, and the bill does not reduce funding for other opioid-response activities—it clarifies that kits are an eligible use of existing money.

Who stands to gain

• naloxone/Narcan manufacturers (increased demand for kits)
• state and tribal health departments (expanded grant flexibility)

Named in the bill

21st Century Cures Act, Section 1003, State and Tribal opioid-response grants, naloxone, opioid overdose reversal kits

Where it stands

7 cosponsors: 6 Democrats, 1 Republicans.

• Sep 10, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 10, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,010,000 in lobbying spend. A filing names 4 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Gabe Amo, the sponsor, reported $670,617 in PAC receipts in the 2026 cycle.

• Emergent Biosolutions Inc — $940,000 on 2 filings
• Emergent Biosolutions Inc. — $70,000 on 1 filing

Lobbying Disclosure Act filings through Jul 19, 2026. A filing shows who paid to lobby on a bill it names, not what changed.